title: Bacillus cereus endophthalmitis following intravitreous bevacizumab injection.
abstract: The first case of Bacillus cereus endophthalmitis following an intravitreous injection of bevacizumab is described. A 77-year-old man presented to a retina specialist with an active choroidal neovascularization related to age-related macular degeneration for which he received intravitreous bevacizumab (1.25 mg) and post-injection topical gatifloxacin. Eight hours later, the patient woke up with excruciating pain and a decline in vision associated with nausea and vomiting. A vitreous biopsy was performed that revealed B. cereus. Despite intravitreous injections of vancomycin and ceftazidime on day 1 and pars plana vitrectomy with repeat intravitreous injections on day 3, the eye did not recover light perception.
authors.affiliation: Cullen Eye Institute, Baylor College of Medicine, 6560 Fannin, Houston, TX, USA.
authors.forename: Andrew C
authors.initials: AC
authors.lastname: Kopel
authors.forename: Petros E
authors.initials: PE
authors.lastname: Carvounis
authors.forename: Eric R
authors.initials: ER
authors.lastname: Holz
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D001409:Bacillus cereus / Q000302:isolation & purification*; D000068258:Bevacizumab; D001766:Blindness / Q000209:etiology; D002442:Ceftazidime / Q000627:therapeutic use; D020256:Choroidal Neovascularization / Q000188:drug therapy; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D009877:Endophthalmitis / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D015818:Eye Infections, Bacterial / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D016908:Gram-Positive Bacterial Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D007267:Injections / Q000009:adverse effects*; D008268:Macular Degeneration; D008297:Male; D014640:Vancomycin / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014821:Vitrectomy; D014822:Vitreous Body / Q000382:microbiology
chemical_list: D020533:Angiogenesis Inhibitors; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D014640:Vancomycin; D002442:Ceftazidime